Antisense restenosis composition and method

• US 7,094,765 B1
• Filed: 01/29/2000
• Issued: 08/22/2006
• Est. Priority Date: 01/29/1999
• Status: Expired due to Term

• Current Assignee: Sarepta Therapeutics, Inc.
• Original Assignee: Avi Biopharma, Inc.
• Inventors: Iversen, Patrick L., Weller, Dwight D.
• Primary Examiner(s): EPPS -SMITH, JANET L
• Application Number:
  US09/493,427
• Time in Patent Office: 2,397 Days
• Field of Search: 514/44, 435/6, 435/325, 435/375, 536/23.1, 536/24.5, 536/24.3, 536/24.33
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 31/07 Retinol compounds, e.g. vitamin A retinoic acids A61K31/203

Abstract

The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having uncharged phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.

Claims

1. A method for treating a vascular injury site in a human patient by reducing restenosis at the site, said method comprising:

administering to the patient, by intravascular delivery directly to the vascular injury site, a morpholino antisense compound having uncharged phosphorodiamidate intersubunit linkages of the form;

2. The method of claim 1, wherein said administering is carried out by injecting the antisense compound from an injection balloon catheter directly into the vascular injury site, under pressure, through injectors contained on the surface of the catheter balloon, wherein the vascular injury site comprises a vascular wall having a tunica media and wherein said injectors are capable of penetrating the tunica media in the vascular wall.

3. The method of claim 2, wherein the catheter balloon has a plurality of outer-facing channels that are connected to a drug-delivery lumen of the catheter, each channel having one or more injection ports, and said injecting includes forcing a solution or suspension of the antisense compound from said drug-delivery lumen through said injection ports when the balloon is in an inflated position.

4. The method of claim 3, wherein the amount of antisense compound administered is between 5 and 20 mg.

5. The method of claim 1, wherein said administering is carried out by contacting the vascular injury site with an intravascular stent having a coating containing the antisense compound in diffusible form.

6. The method of claim 5, wherein the coating is designed to release the majority of the antisense compound in the coating over a period of 5–

60 minutes following balloon angioplasty.

7. The method of claim 6, wherein the intravascular stent is biodegradable.

8. A method for treating a vascular injury site in a human patient, said method comprising:

providing an intravascular stent wherein said stent or a coating on said stent contains a morpholino antisense compound in diffusible form, wherein the morpholino antisense compound has uncharged phosphorodiamidate intersubunit linkages of the form;

9. The method of claim 8, wherein the coating is designed to release the majority of the antisense compound in the coating over a period of 5–

60 minutes following balloon angioplasty.

10. The method of claim 8, wherein the stent is biodegradable.

11. The method of claim 8, wherein the compound is derivatized with a moiety that enhances the solubility of the compound in aqueous medium, to a level of at least about 30 mg/ml of the antisense compound.

12. The method of claim 11, wherein said moiety is triethyleneglycol attached to the 5′

end of the compound.

13. The method of claim 8, wherein said contacting comprises placing the stent at the vessel site at the time of balloon angioplasty or during coronary bypass surgery.